Table 1.
Baseline characteristics of the study patients
| Variables | All patients (N=848) |
|---|---|
| Age (y)* | 58 (49-65) |
| Gender (male/female) | 732/116 |
| HBsAg (positive/negative) | 680/168 |
| HCV antibody (positive/negative) | 24/824 |
| Albumin (g/L)* | 37(34-41 ) |
| Bilirubin (umol/L)* | 12.2 (8.8-17.4) |
| GGT (IU/L)* | 123.0 (71.3-217.8) |
| ALT (IU/L)* | 40.5 (26.0-63.0) |
| Prothrombin time (s)* | 12.7 (11.9-13.7) |
| AFP (ng/mL) * | 264.0 (12.0-5359.5) |
| Child-Pugh grade (A/B) | 808/40 |
| Tumor size, diameter of largest tumor (cm)* | 8.0 (5.0-10.0) |
| Tumor number (1/2/3/>3) | 369/169/98/212 |
| TACE sessions* | 3(2-4) |
| Combined treatment (PEI, RFA, microwave/ external radiotherapy/sorafenib) | 89/21/16 |
| BCLC B subclassification (B1/B2/B3+B4) | 181/468/199 |
| Survival times, median (95% CI) | 18.0 (16.0-20.0) |
*Values are medians, with interquartile ranges shown in parentheses. HbsAg: hepatitis B virus surface antigen; HCV: hepatitis C virus; BCLC: Barcelona Clinic Liver Cancer; AFP: α-fetoprotein; GGT: γ-glutamyltranspeptidase; ALT: alanine aminotransferase.